Spain Liquid
Biopsy market is anticipated to witness a growth of steady CAGR in the forecast
period, 2024-2028. The liquid Biopsy market in Spain has witnessed significant
growth over the past few years, owing to the increasing investments in the liquid
biopsy market in the country. In recent years, liquid biopsy has emerged as a promising
diagnostic technique for the detection and monitoring of cancer and other
diseases. As a result, the liquid biopsy market in Spain has been attracting
increasing investments from both public and private sectors. These investments
are helping to drive the growth of the liquid biopsy market in Spain, which is
expected to continue to grow rapidly in the coming years.
One of the
primary drivers of investment in the liquid biopsy market in Spain is the
potential for liquid biopsy to transform cancer diagnosis and treatment.
Traditional biopsy methods, which involve invasive procedures such as surgery
or needle biopsy, can be painful, risky, and time-consuming. Liquid biopsy, on
the other hand, is a non-invasive technique that can provide faster, more accurate,
and less expensive diagnostic results. This potential for improved cancer care
has attracted significant investment in liquid biopsy research and development
in Spain.
Another driver
of investment in the liquid biopsy market in Spain is the increasing prevalence
of cancer in the country. According to the Spanish Society of Medical
Oncology, cancer is the second leading cause of death in Spain, accounting for
nearly 30% of all deaths. Also, according to the latest statistics,
approximately 277,394 new cancer cases were diagnosed in Spain in 2020. This
has created a significant demand for more effective and efficient cancer
diagnosis and treatment, and liquid biopsy has the potential to meet this
demand. Several factors contribute to the rising prevalence of cancer in Spain.
One of the primary causes is the aging population. As the population of Spain
ages, the risk of developing cancer increases significantly. According to
the National Institute of Statistics, the percentage of people aged 65 and over
in Spain increased from 19.2% in 2010 to 21.8% in 2020. This increase in
the elderly population has led to a higher incidence of cancer.
Furthermore,
the Spanish government has been actively supporting investment in the liquid
biopsy market. In addition to government support, private sector investments in
the liquid biopsy market in Spain are on the rise. Several startups and
established companies in Spain are investing in liquid biopsy research and
development, and some have already launched liquid biopsy products in the
market. For example, Biocartis has launched a liquid biopsy test for
colorectal cancer that is designed to be used with its diagnostic platform,
Idylla.
Advancements in Liquid Biopsy Technology
One of the major advancements in liquid biopsy technology is the
development of next-generation sequencing (NGS) technology. NGS technology
allows for the analysis of multiple biomarkers simultaneously, providing more
comprehensive information about the disease. This technology has significantly
improved the accuracy and sensitivity of liquid biopsy tests, allowing for the
detection of cancer at an early stage. NGS technology has enabled the detection
of rare mutations that were previously undetectable, providing clinicians with
more information about the disease and its progression.
Another significant advancement in liquid biopsy technology is the
development of digital PCR (dPCR) technology. dPCR technology is a more precise
and sensitive method of detecting and quantifying cancer biomarkers in body
fluids. This technology has improved the accuracy of liquid biopsy tests,
reduced false-negative results, and improved patient outcomes.
Liquid biopsy technology has been improved by the development of
microfluidic devices. These devices allow for the isolation and analysis of
circulating tumor cells (CTCs) and cell-free DNA (cfDNA) from body fluids. This
technology has significantly improved the sensitivity and specificity of liquid
biopsy tests, enabling the detection of cancer at an early stage.
In addition, the development of machine learning and artificial
intelligence (AI) algorithms has significantly improved the accuracy and
reliability of liquid biopsy tests. These algorithms can analyze large datasets
and identify patterns that may be indicative of cancer, providing clinicians
with more accurate and reliable diagnostic information.
The development of liquid biopsy technology in Spain has been driven by
government support for research and development activities, increasing
investments in the market, and collaborations between academic institutions and
industry partners. These efforts have led to the development of new liquid
biopsy assays and technologies that are more accurate, reliable, and cost-effective.
Download Free Sample Report
Growing
Adoption of Non-Invasive Diagnostic Techniques
Non-invasive
diagnostic techniques have been gaining popularity in recent years,
particularly in Spain, due to their convenience, safety, and accuracy.
Non-invasive diagnostic techniques are medical tests that do not require the
insertion of instruments or devices into the body, such as blood tests,
ultrasound, and magnetic resonance imaging (MRI). In Spain, the adoption of
non-invasive diagnostic techniques has been driven by several factors,
including the increasing prevalence of chronic diseases, the aging population,
and technological advancements.
One
of the primary drivers of the growing adoption of non-invasive diagnostic
techniques in Spain is the increasing prevalence of chronic diseases. Chronic
diseases, such as cancer, cardiovascular disease, and diabetes, require ongoing
monitoring and management. Non-invasive diagnostic techniques are well-suited
for monitoring chronic diseases, as they can be performed more frequently and
with less risk to the patient.
Moreover,
the aging population in Spain has contributed to the growing adoption of
non-invasive diagnostic techniques. As people age, they are more likely to
develop chronic diseases and traditional diagnostic techniques may be more
invasive and riskier for older adults. Non-invasive diagnostic techniques, such
as ultrasound and MRI, are safer and more comfortable for older adults, making
them a preferred option for diagnostic testing.
Technological
advancements have played a significant role in the growing adoption of
non-invasive diagnostic techniques in Spain. Advancements in medical imaging,
such as ultrasound and MRI, have improved the accuracy and specificity of
diagnostic tests, reducing the need for more invasive procedures, such as
biopsies. In addition, the development of new blood tests, such as liquid
biopsy, has enabled the detection and monitoring of diseases, such as cancer,
without the need for invasive procedures.
The
growing adoption of non-invasive diagnostic techniques in Spain has several
benefits. Non-invasive techniques are less invasive and painful, reducing
patient discomfort and improving patient satisfaction. Moreover, non-invasive
techniques are generally safer than invasive procedures, reducing the risk of
complications and infections. Hence, this technique can be performed more
frequently, enabling earlier detection and more effective management of
diseases.
Government
Support for Liquid Biopsy Research in Spain
The
Spanish government has been investing heavily in research and development
activities related to liquid biopsy technology. The government has provided
funding for academic institutions, research centres, and private companies to
support the development of new liquid biopsy assays, devices, and technologies.
This funding has enabled researchers to conduct more extensive studies and
accelerate the development of new liquid biopsy tests.
In
addition to funding, the Spanish government has been providing regulatory
support for the development of liquid biopsy technology. The government has
been working with regulatory agencies to streamline the approval process for
new liquid biopsy tests, enabling researchers to bring new tests to market more
quickly. This regulatory support has been critical in enabling researchers to
commercialize new liquid biopsy tests, which can improve patient outcomes and
reduce the burden of disease.
Furthermore,
the Spanish government has been promoting collaboration between academic
institutions and industry partners to advance liquid biopsy research. These
collaborations have enabled researchers to share resources, knowledge, and
expertise, which can accelerate the development of new liquid biopsy tests. The
government has been providing incentives for private companies to invest in
liquid biopsy research, such as tax breaks and grants.
For
example, researchers in Spain have developed liquid biopsy tests that can
detect cancer at an early stage and identify rare mutations that were
previously undetectable.
The
government's support for liquid biopsy research in Spain has several benefits.
By supporting the development of new liquid biopsy tests, the government is
enabling clinicians to diagnose diseases more accurately and monitor disease
progression more effectively. This can improve patient outcomes and reduce the
burden of disease. Moreover, the development of liquid biopsy technology can create
new jobs and stimulate economic growth.
Market
Segmentation
Spain liquid biopsy market can be segmented
by offering, technology, workflow, sample, circulating
biomarker, application, end user, and by region. Based on offering, the market can
be segmented into testing service, kits, platform, and other consumables. Based
on technology, the market can be divided into polymerase chain reactions, next
generation sequencing, and others. Based on workflow, the market can be categorized
into sample preparation, library preparation,
sequencing, and data analysis & management. Based on sample, the market can
be fragmented into blood, urine, saliva, and others. Based on circulating
biomarker, the market can be segmented into circulating tumor cells (CTCs), cell
free nucleic acids, exosomes & extracellular vesicles, and others. Based on
application, the market can be split into oncological and non-oncological. The Oncological
segment can be sub-segmented into breast cancer, lung cancer, prostate cancer,
colorectal cancer, and others while the non-Oncological segment can be divided
into treatment monitoring, prognosis & recurrence monitoring, treatment
selection, and others. Based on end user, market can be categorized into clinical
laboratories, academic & research institutes, and pharmaceutical &
biotechnology companies.
Market Players
Thermo Fisher Scientific SL, Sysmex
Espana S.L., OncoDNA SA, Atrys Health SA, Biocartis Group NV, are some of the leading
players operating in the Spain Liquid Biopsy market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 –
2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024
– 2028
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
By Offering
By Technology
By Workflow
By Sample
By Circulating Biomarker
By Application
By End User
By Region
|
|
Regional
scope
|
Central
Region North Spain; Aragon & Catalonia; Andalusia, Murcia & Valencia;
Madrid, Extremadura & Castilla
|
|
Key
companies profiled
|
Thermo Fisher Scientific SL, Sysmex Espana S.L., OncoDNA SA,
Atrys Health SA, Biocartis Group NV
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, Spain Liquid Biopsy market has been segmented into
following categories, in addition to the industry trends which have also been
detailed below:
·
Spain Liquid Biopsy Market, By Offering:
o Testing Service
o Kits
o Platform
o Other Consumables
·
Spain Liquid Biopsy Market, By Technology:
o Polymerase Chain Reactions
o Next Generation Sequencing
o Others
·
Spain Liquid Biopsy Market, By Workflow:
o Sample Preparation
o Library Preparation
o Sequencing
o Data Analysis & Management
·
Spain Liquid Biopsy Market, By Sample:
o Blood
o Urine
o Saliva
o Others
·
Spain Liquid Biopsy Market, By Circulating Biomarker:
o Circulating Tumor Cells (CTCs)
o Cell Free Nucleic Acids
o Exosomes & Extracellular
Vesicles
o Others
·
Spain Liquid Biopsy Market, By Application:
o Oncological
§ Breast Cancer
§ Lung Cancer
§ Prostate Cancer
§ Colorectal Cancer
§ Others
o non-Oncological
§ Treatment Monitoring
§ Prognosis & Recurrence
Monitoring
§ Treatment Selection
§ Others
·
Spain Liquid Biopsy Market, By End User:
o Clinical Laboratories
o Academic & Research
Institutes
o Pharmaceutical &
Biotechnology Companies
·
Spain
Liquid Biopsy Market, By Region:
o Central Region North Spain
o Aragon & Catalonia
o Andalusia, Murcia & Valencia
o Madrid, Extremadura &
Castilla
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Spain Liquid Biopsy Market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
Spain Liquid Biopsy Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]